Edition:
India

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

15.61USD
22 Nov 2017
Change (% chg)

$-0.23 (-1.45%)
Prev Close
$15.84
Open
$15.82
Day's High
$15.86
Day's Low
$15.56
Volume
280,383
Avg. Vol
393,731
52-wk High
$19.94
52-wk Low
$13.44

Latest Key Developments (Source: Significant Developments)

Ironwood Pharma files for potential mixed shelf offering
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​.  Full Article

Ironwood Pharmaceuticals Q3 non-GAAP loss per share $0.18
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Ironwood Pharmaceuticals Inc :Q3 non-GAAP loss per share $0.18.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Ironwood Pharmaceuticals provides third quarter 2017 investor update.Q3 loss per share $0.22.Q3 revenue $87 million versus I/B/E/S view $73.6 million.Ironwood Pharmaceuticals Inc sees 2017 ‍R&D expenses to be in low-to-middle end of previously guided $145 million to $160 million range​.Ironwood Pharmaceuticals Inc - ‍data from two phase IIa studies with IW-1973 in diabetic patients with hypertension are expected by end of 2017​.Ironwood Pharmaceuticals Inc - ‍to use less than $110 million in cash for operations in 2017, up from less than $100 million previously guided​.Ironwood - sees co & Allergan's ‍combined total 2017 marketing & sales expenses for Linzess in middle of previously guided $250 million to $280 million range​.Ironwood Pharmaceuticals Inc - co & Allergan no longer intend to pursue linaclotide delayed release-1​.  Full Article

Ironwood Pharma Q2 adj shr loss $0.16
Friday, 5 Aug 2016 

Ironwood Pharmaceuticals Inc : Ironwood pharmaceuticals provides second quarter 2016 investor update . Q2 gaap loss per share $0.15 . Q2 revenue $54.4 million versus i/b/e/s view $55.5 million . Q2 non-gaap loss per share $0.16 . Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S . Allergan and ironwood continue to expect total 2016 marketing and sales expenses for linzess to be in range of $230 million to $260 million . Says continues to expect to use less than $70 million in cash for operations in 2016 . Q2 earnings per share view $-0.15, revenue view $55.5 million -- Thomson Reuters I/B/E/S Further company coverage: [IRWD.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Allergan says supplemental NDA for 72 mcg Linaclotide accepted for FDA review
Thursday, 9 Jun 2016 

Allergan Plc : FDA prescription drug user fee act (PDUFA) target action date is expected to occur in early 2017 . FDA accepted for review SNDA for 72 mcg dose of Linaclotide for use in treatment of adults with chronic idiopathic constipation .Ironwood and Allergan announce supplemental new drug application for 72 mcg Linaclotide in chronic idiopathic constipation has been accepted for FDA review.  Full Article

Ironwood Pharmaceuticals Q1 gaap loss per share $0.09
Tuesday, 10 May 2016 

Ironwood Pharmaceuticals Inc : Ironwood on track to achieve positive cash flow in 2018 . Ironwood pharmaceuticals provides first quarter 2016 investor update . Q1 non-gaap loss per share $0.08 . Q1 gaap loss per share $0.09 . Q1 revenue $66 million versus i/b/e/s view $53.6 million .Q1 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Ironwood Pharma files for potential mixed shelf offering

* Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​ Source text: (http://bit.ly/2h08KF7) Further company coverage: